Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(145 products)
- Bcr-Abl(102 products)
- EGFR(572 products)
- FAK(72 products)
- FLT(92 products)
- Fibroblast Growth Factor Receptor (FGFR)(170 products)
- JAK(245 products)
- PDGFR(126 products)
- RAAS(86 products)
- Src(78 products)
- Syk(38 products)
- Thrombin(47 products)
- VDA(2 products)
- VEGFR(268 products)
Show 6 more subcategories
Found 1414 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
PROTAC EGFR degrader 2
<p>Potent PROTAC EGFR degrader 2; IC50: 4.0 nM, DC50: 36.51 nM; inhibits cell growth; for NTR-responsive synthesis.</p>Formula:C58H72ClFN12O8SColor and Shape:SolidMolecular weight:1151.78MLK3-IN-1
<p>MLK3-IN-1 (Compound 37) is a selective inhibitor of mixed-lineage kinase 3 (MLK3) with an IC50 of less than 1 nM. It also inhibits FAK with an IC50 of 15.5 μM. In both murine and human liver microsomes, MLK3-IN-1 demonstrates excellent metabolic stability.</p>Formula:C20H16F6N4O2SColor and Shape:SolidMolecular weight:490.422Apoptosis inducer 35
<p>Apoptosisinducer 35 (Compound 6) is a multi-target inhibitor that reduces the expression of EGFR, AKT, ERK, and P38-MAPKα. It suppresses the proliferation of cancer cells A549 and Jurkat, induces cell cycle arrest at the S phase, and triggers apoptosis (cell death).</p>Formula:C23H21ClN8O2S2Color and Shape:SolidMolecular weight:541.048Caffeic acid-pYEEIE
CAS:<p>Phosphopeptide ligand for the src SH2 domain (IC50 = 42 nM); displays 30-fold higher affinity than N-acetyl-O-phosphono-Tyr-Glu-Glu-Ile-Glu (Ac-pYEEIE,).</p>Formula:C39H50N5O19PPurity:98%Color and Shape:SolidMolecular weight:923.82SJ1008030
CAS:<p>SJ1008030, a JAK2 PROTAC, degrades JAK2; EC50: 5.4 nM, IC50: 32.09 nM in MHH-CALL-4 cells for leukemia research.</p>Formula:C42H43N13O7SColor and Shape:SolidMolecular weight:873.94Syk-IN-4
<p>Syk-IN-4: potent, selective SYK inhibitor, orally bioavailable, IC50=0.31 nM, targets autoimmunity, cancers.</p>Color and Shape:SolidDSPE-PEG5000-GE11
<p>DSPE-PEG5000-GE11 is a PEG compound composed of DSPE and the EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells with EGFR overexpression. DSPE-PEG5000-GE11 is utilized in drug delivery.</p>Color and Shape:Odour SolidFLT3-IN-29
<p>FLT3-IN-29 (Compound MY-10) is an FLT3 inhibitor with IC50 values of 6.5 nM and 10.3 nM for FLT3-ITD and FLT3-D835Y mutants, respectively. It induces cell cycle arrest at the G0/G1 phase and effectively triggers apoptosis (Apoptosis). Additionally, FLT3-IN-29 reduces reactive oxygen species (ROS) and mitochondrial membrane potential (MMP), displaying anti-leukemic properties.</p>Formula:C25H30N6O2Color and Shape:SolidMolecular weight:446.545BMS-599626 2HCL(714971-09-2 Free base)
CAS:<p>BMS-599626 2HCL (AC480 2HCl) is a BMS-599626 derivative.</p>Formula:C27H29Cl2FN8O3Purity:99.11%Color and Shape:Odour SolidMolecular weight:603.47JAK1/TYK2-IN-1
CAS:<p>JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 ( IC 50 = 29 and 41 nM respectively).</p>Formula:C18H20F3N7OColor and Shape:SolidMolecular weight:407.401JAK3-IN-14
CAS:<p>JAK3-IN-14 is a potent, selective and orally active FLT3 inhibitor, with IC50s of ∼40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively.</p>Formula:C18H13N3OPurity:98.29%Color and Shape:SoildMolecular weight:287.32Emodic acid
CAS:<p>Emodic acid is a useful organic compound for research related to life sciences. The catalog number is T124807 and the CAS number is 478-45-5.</p>Formula:C15H8O7Color and Shape:SolidMolecular weight:300.222PTD10
CAS:<p>PTD10, a highly potent PROTAC BTK degrader, exhibits a DC50 of 0.5 nM and a KD of 2.28 nM.</p>Formula:C49H51N11O8Purity:98%Color and Shape:SolidMolecular weight:922EGFR-IN-110
<p>EGFR-IN-110 (Compound 6) is a covalent inhibitor of EGFR, demonstrating pIC50 values of 9.2 for the EGFR enzyme and 8.7 for EGFR cells. It exhibits strong efficacy in targeting EGFR and maintains good kinase selectivity.</p>Formula:C22H16ClFN4O2Molecular weight:422.09458EGFR-IN-22
CAS:<p>EGFR-IN-22: potent for EGFR (IC50: 4.91 nM) & L858R/T790M/C797S mutation (IC50: 0.54 nM).</p>Formula:C38H47BrFN10O2PColor and Shape:SolidMolecular weight:805.72Angiogenesis related Compound Library
<p>A unique collection of 1353 proangiogenic and antiangiogenic compounds for new targets identification, research in mechanisms of angiogenesis, and high</p>Color and Shape:Odour SolidEGFR/CDK2-IN-2
<p>EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.</p>Formula:C49H32N12O2S2Purity:98%Color and Shape:SolidMolecular weight:884.99SNIPER(ABL)-050
<p>SNIPER(ABL)-050 is a chemical compound that combines Imatinib, an ABL inhibitor, with MV-1, an IAP ligand, using a linker.</p>Formula:C68H84N12O9Purity:98%Color and Shape:SolidMolecular weight:1213.47Multi-target kinase inhibitor 2
<p>Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 values</p>Purity:98%Color and Shape:Odour SolidMET/PDGFRA-IN-1
<p>MET/PDGFRA-IN-1 (compound 8c) serves as an inhibitor of MET and PDGFRA proteins, displaying an IC50 of 36 μM against MET.</p>Formula:C26H23N7OPurity:98%Color and Shape:SolidMolecular weight:449.51KIT/PDGFRA-IN-1
<p>KIT/PDGFRA-IN-1 (compound 19) is an inhibitor targeting the stem cell growth factor receptor (KIT) and platelet-derived growth factor receptor alpha (PDGFRA). Its IC50 values are 2.3 µM for KIT-wt, 12 µM for KIT-D816H, 492 µM for KIT-T670I, 0.8 µM for PDGFRA-wt, 99.9 µM for PDGFRA-D842V, 42.3 µM for PDGFRA-T674I, and 4.3 µM for PDGFRA-G680R. The GR50 values for GIST-T1, T1-a-D842V, and GIST-48B cell lines (gastrointestinal stromal tumor cell lines with PDGFR and KIT mutations) are 12 nM, 8900 nM, and ≥10,000 nM, respectively.</p>Formula:C26H18F3N5O2Color and Shape:SolidMolecular weight:489.449PROTAC EGFR degrader 7
<p>Compound 13b, a potent EGFR degrader, inhibits and induces apoptosis in NSCLC cells with a DC50 of 13.2 nM.</p>Formula:C46H48N10O6Color and Shape:SolidMolecular weight:836.94Bemarituzumab
CAS:<p>Bemarituzumab: humanized IgG1 antibody inhibits FGFR2b, may be used in cancer research.</p>Purity:SDS-PAGE:95% SEC-HPLC:99.99%Color and Shape:LiquidMolecular weight:144 kDaAS2553627
CAS:<p>AS2553627 is a JAK inhibitor. AS2553627 prevents chronic rejection in rat cardiac allografts.</p>Formula:C18H19N5OColor and Shape:SolidMolecular weight:321.38INCB-000928
CAS:<p>Zilurgisertib (INCB-000928) is a selective and potent ALK 2 inhibitor for the study of cancer and MF anemia.</p>Formula:C30H38N4O3Purity:98.93%Color and Shape:SolidMolecular weight:502.65EGFR-IN-93
<p>EGFR-IN-93 (compound 18) is an allosteric inhibitor of the T790M/L858R double mutant EGFR. It is applicable for research in non-small cell lung cancer (NSCLC).</p>Formula:C22H18FN3O3Molecular weight:391.13322HIF-1 Signaling Pathway Compound Library
<p>A unique collection of 1336 HIF-1 related small chemicals can be used for drug discovery in ischemic disease and cancer and related mechanism studies；</p>Color and Shape:Odour SolidAG-1478 hydrochloride
CAS:<p>AG1478 HCl is an epidermal growth factor receptor protein inhibitor.</p>Formula:C16H15Cl2N3O2Color and Shape:SolidMolecular weight:352.21FGFR2 degrader 1
<p>FGFR2 degrader1 (compound 28E) is a selective PROTACS degrader of FGFR2, with a DC50 of 0.645 nM. FGFR2 plays a significant role in cancer research.</p>Formula:C40H39Cl2N9O6Molecular weight:811.24004Sorafenib-d4
CAS:<p>Sorafenib D4 is deuterium-labeled Sorafenib, a multi-kinase inhibitor (Raf-1, B-Raf, VEGFR-3) with IC50s: 6, 20, 22 nM.</p>Formula:C21H16ClF3N4O3Purity:98%Color and Shape:SolidMolecular weight:468.85PROTAC TYK2 degradation agent1
CAS:<p>PROTAC TYK2 Agent1 selectively degrades TYK2, with a 14 nM DC50, for autoimmune research.</p>Formula:C55H69N13O7SPurity:98%Color and Shape:SolidMolecular weight:1056.28MPT0B390
CAS:<p>MPT0B390 is an inhibitor of HDAC and a TIMP3 inducer inhibiting tumor growth, metastasis, and angiogenesis.</p>Formula:C17H17N3O5SPurity:99.4%Color and Shape:SolidMolecular weight:375.4cep-5214
CAS:<p>CEP-5214: Powerful pan VEGF-R tyrosine kinase inhibitor; IC50: 16nM (R1), 8nM (R2), 4nM (R3); effective in cells.</p>Formula:C28H28N2O3Color and Shape:SolidMolecular weight:440.53EGFR-IN-42
<p>EGFR-IN-42 (17b) is a potent EGFR inhibitor with nanomolar efficacy, merging tamoxifen/endoxifen and gefitinib, exhibiting enhanced anti-cancer action.</p>Formula:C49H53ClFN5O5Color and Shape:SolidMolecular weight:846.43PACAP-38 (31-38), human, mouse, rat
CAS:<p>PACAP-38 (31-38), human, mouse, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production</p>Formula:C47H83N17O11Purity:98%Color and Shape:SolidMolecular weight:1062.27EGFR/HER2/DHFR-IN-3
<p>EGFR/HER2/DHFR-IN-3 (compound 4c) serves as an efficacious dual inhibitor specifically targeting EGFR/HER2, exhibiting IC50 values of 0.138 μM for EGFR and 0.</p>Purity:98%Color and Shape:Odour SolidPROTAC EGFR degrader 4
CAS:<p>PROTAC EGFR degrader 4 targets mutant EGFR, degrades del19 and L858R/T790M (DC50: 0.51, 126 nM), and inhibits HCC827, H1975 cell growth (IC50: 0.83, 203.1 nM).</p>Formula:C55H70N12O4SColor and Shape:SolidMolecular weight:995.29DB1113
CAS:<p>DB1113 is a bifunctional kinase degrader, targeting ABL1, ABL2, CDK4, MAPKs, and more for disease research.</p>Formula:C59H68F3N13O6SColor and Shape:SolidMolecular weight:1144.31VSLRGDTRG acetate
<p>VSLRGDTRG acetate is a synthetic peptide of the RGD motif from cadherin17 (CDH17), capable of binding to α2β1 integrin and activating its signaling pathways. It facilitates the high-affinity conformational change of β1 integrin via the RGD motif, enhancing cell adhesion and phosphorylation of FAK and ERK1/2, thereby promoting tumor proliferation and metastasis. VSLRGDTRG acetate is applicable in research on cancers expressing CDH17, such as colon and pancreatic cancers.</p>Color and Shape:Odour SolidSNIPER(ABL)-033
CAS:<p>SNIPER(ABL)-033, a compound that conjugates HG-7-85-01 (ABL inhibitor) to a LCL161 derivative (IAP ligand) via a linker, effectively reduces BCR-ABL protein</p>Formula:C61H73F3N10O9S2Purity:98%Color and Shape:SolidMolecular weight:1211.42PROTAC FLT3/CDK9 degrader-1
<p>Potent PROTAC degrader for FLT3/CDK9, induces apoptosis, and shows promise for FLT3-ITD mutated AML research.</p>Formula:C48H62N12O7Color and Shape:SolidMolecular weight:919.08ALK-IN-9
CAS:<p>ALK-IN-9 effectively inhibits cell growth with IC50 <0.2 nM for Ba/F3-EML4-ALK, KM12, KG-1.</p>Formula:C20H21FN6O3Color and Shape:SolidMolecular weight:412.425Sozinibercept
CAS:<p>Sozinibercept (OPT 302; VGX-300), a VEGFR-3 inhibitor, blocks VEGF-C/D to curb angiogenesis and vascular leakage, and treats rat diabetic retinal edema.</p>Color and Shape:LiquidGefitinib N-oxide hydrochloride
<p>Gefitinib N-oxide hydrochloride is an N-oxide of EGFR inhibitor Gefitinib with IC50 of 2-37 nM.</p>Formula:C22H24ClFN4O41·5HClColor and Shape:SolidMolecular weight:517.59BTK-IN-5
CAS:<p>BTK-IN-5 is a covalent inhibitor of Bruton's tyrosine kinase (BTK) designed for the treatment of medical conditions including cardiovascular diseases,</p>Formula:C23H32N4O5Color and Shape:SolidMolecular weight:444.532SNIPER(ABL)-049
<p>SNIPER(ABL)-049, a compound that conjugates Imatinib (ABL inhibitor) with Bestatin (IAP ligand) through a linker, effectively reduces BCR-ABL protein levels,</p>Formula:C52H66N10O8Purity:98%Color and Shape:SolidMolecular weight:959.14M4K2234
CAS:<p>M4K2234 (26b) inhibits ALK2/ALK5 (IC50: 5/2144 nM), used as a probe for ALK1/2 kinases in cancer research.</p>Formula:C27H31FN4O2Color and Shape:SolidMolecular weight:462.56PROTAC BTK Degrader-6
CAS:<p>PROTAC BTK Degrader-6 (Compound 15), with a DC50 of 3.18 nM, exhibits anti-inflammatory properties by inhibiting NF-κB activation and suppressing the expression</p>Formula:C45H47N11O6Purity:98%Color and Shape:SolidMolecular weight:837.92TYK2 activator-1
<p>TYK2activator-1 (16b) is a TYK2 activator with an EC50 value of 1.78 μM. It inhibits JAK2 and JAK3 with IC50 values of 6.8 μM and 6.3 μM, respectively.</p>Formula:C23H21FN4O2Color and Shape:SolidMolecular weight:404.16485PF15 TFA
<p>PF15 TFA, a PROTAC targeting FLT3 kinase and CRBN, exhibits selective degradation of FLT3-ITD with a DC50 of 76.7 nM.</p>Formula:C46H50F3N13O8Purity:98%Color and Shape:SolidMolecular weight:969.97SI-2
CAS:<p>SI-2, a SRC-3 inhibitor, triggers breast cancer cell death (IC50: 3-20 nM), sparing normal cells.</p>Formula:C15H15N5Purity:98.4%Color and Shape:SolidMolecular weight:265.31VEGFR-2-IN-64
<p>VEGFR-2-IN-64 (Compound 28) is an inhibitor of VEGFR2 with an IC50 of 27.8 nM. It suppresses the proliferation of cancer cells A549, T-47D, and Caco-2, exhibits anti-migration and anti-colony formation activities in T-47D cells, and induces apoptosis in T-47D cells.</p>Formula:C72H123N9O6Color and Shape:SolidMolecular weight:1210.87-Hydroxyneolamellarin A
CAS:<p>7-Hydroxyneolamellarin A, from Dendrilla nigra, inhibits HIF-1α and VEGF in cancer research.</p>Formula:C24H19NO5Color and Shape:SolidMolecular weight:401.41U3-1565
<p>U3-1565 (Anti-HB-EGF antibody) is an antibody targeting HB-EGF with potential anti-tumor activity, used in the study of advanced solid tumors.</p>Color and Shape:LiquidMolecular weight:144.82 kDa (Predicted)Nezutatug
CAS:<p>Nezutatug, an anti-HER3 antibody, serves as a research tool in cancer studies [1].</p>Purity:98%Color and Shape:LiquidEfimosfermin alfa
<p>Efimosfermin alfa is a humanized antibody targeting FGFR1.</p>Color and Shape:Odour LiquidSJ10542
CAS:<p>SJ10542: potent JAK2/3-targeting PG-PROTAC; DC50s: JAK2 - 14 nM, JAK3 - 11 nM, JAK2-fusion ALL - 24 nM; CRBN recruiter.</p>Formula:C41H46N12O5SColor and Shape:SolidMolecular weight:818.95Tomuzotuximab
CAS:<p>Tomuzotuximab: fully human, glycoengineered IgG1 anti-EGFR monoclonal antibody with anticancer properties.</p>Color and Shape:LiquidIstiratumab
CAS:<p>Istiratumab (M-6495) is a bispecific antibody against IGF-1R/ErbB3 for cancer research, promoting receptor degradation.</p>Color and Shape:LiquidPROTAC EGFR degrader 5
CAS:<p>PROTAC EGFR degrader 5 effectively breaks down EGFR Del19 in HCC827 cells at 34.8 nM, inducing apoptosis and G1 arrest.</p>Formula:C57H72FN13O5SColor and Shape:SolidMolecular weight:1070.33FAK PROTAC B5
CAS:<p>FAK PROTAC B5: a degrader with 14.9 nM IC50, strong degradation, anti-growth, good plasma stability, and fair permeability.</p>Formula:C41H43ClN10O7Color and Shape:SolidMolecular weight:823.3HER2-IN-14
CAS:<p>HER2-IN-14 (Compound 34) is a potent inhibitor of HER2, achieving an inhibitory concentration (IC50) of 18 nM.</p>Formula:C26H23ClF2N8O3Color and Shape:SolidMolecular weight:568.96Coprelotamab
CAS:<p>Coprelotamab (GB-221) is an IgG-κ monoclonal antibody that targets EGFR2, frequently produced in CHO DG44 (Chinese Hamster Ovary) cells [1].</p>Purity:98%Color and Shape:LiquidFLT3-IN-20
<p>FLT3-IN-20 (compound 34f) is a potent FLT3 inhibitor, demonstrating IC50 values of 1 nM for FLT3-D835Y and 4 nM for FLT3-ITD.</p>Formula:C28H33N7O2SColor and Shape:SolidMolecular weight:531.67VEGFR-2-IN-36
<p>VEGFR-2-IN-36 (compound 15) serves as a potent VEGFR-2 inhibitor, exhibiting an IC50 value of 0.067 μM, and acts as an apoptosis inducer with demonstrated</p>Formula:C24H23N7O5Purity:98%Color and Shape:SolidMolecular weight:489.48EGFR-IN-15
CAS:<p>EGFR-IN-15 (compound I-005) is a potent EGFR inhibitor, exhibiting an IC50 value of 4 nM. This compound holds potential for oncological research applications.</p>Formula:C24H25BrN6O2Color and Shape:SolidMolecular weight:509.408Anticancer agent 133
<p>Compound Rh2 (Anticancer agent 133) is a cytotoxic and antimetastatic agent that induces cell cycle arrest, apoptosis, and autophagy.</p>Formula:C24H19Cl3N5ORhPurity:98%Color and Shape:SolidMolecular weight:602.71AST5902
CAS:<p>AST5902 is the active metabolite of Alflutinib.</p>Formula:C27H29F3N8O2Purity:98%Color and Shape:SolidMolecular weight:554.57JAK 3 inhibitor IV
CAS:<p>JAK 3 inhibitor IV (ZM 39923 hydrochloride) is a JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to</p>Formula:C16H19NOPurity:98%Color and Shape:SolidMolecular weight:241.33Os30
<p>Os30 is a potent fourth-generation EGFR inhibitor, specifically targeting the EGFRC797S-TK mutation with IC50 values of 18 nM for EGFRDel19/T790M/C797S TK and</p>Purity:98%Color and Shape:Odour SolidZeteletinib hemiadipate
CAS:<p>Zeteletinib hemiadipate (BOS-172738; DS-5010) is an oral RET kinase blocker with nanomolar potency and strong anti-tumor properties.</p>Formula:C56H56F6N8O12Color and Shape:SolidMolecular weight:1147.098GSK143
CAS:<p>GSK143: Oral SYK inhibitor, pIC50=7.5, curbs pErk, anti-inflammatory, hinders immune cells in mice.</p>Formula:C17H22N6O2Color and Shape:SolidMolecular weight:342.403Caxmotabart
<p>Caxmotabart is a humanized IgG1κ antibody targeting ERBB2, with HumanIgG1kappa, Isotype Control as its corresponding isotype control.</p>Color and Shape:Odour LiquidBV02
CAS:<p>BV02 blocks 14-3-3 interactions, useful in chronic myeloid leukemia research, targets T315I mutant and wild-type Bcr-Abl cells.</p>Formula:C20H15N3O5Purity:99.82%Color and Shape:SolidMolecular weight:377.35SNIPER(ABL)-039
CAS:<p>SNIPER(ABL)-039, conjugating Dasatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of</p>Formula:C54H68ClN11O9S2Purity:98%Color and Shape:SolidMolecular weight:1114.77MHES0488A
<p>MHES0488A is a selective humanized antibody targeting HER2, with a KD value of 0.8 nM. It constitutes the antibody portion of DHES0815A. Upon cellular internalization, MHES0488A is transported to lysosomes, releasing PBD-monoamide into the nucleus, where it alkylates DNA, inducing DNA damage and apoptosis. It shows potential for research in cancers such as HER2-positive breast cancer and gastric cancer.</p>Color and Shape:Odour LiquidRR-src
CAS:<p>Tyrosine kinase substrate peptide</p>Formula:C64H106N22O21Purity:98%Color and Shape:Lyophilized PowderMolecular weight:1519.66FDU73
<p>FDU73 is a potent and selective BTK PROTAC degrader with a DC50 of 2.9 nM in JeKo-1 cells. It inhibits tumor cell proliferation and exhibits antitumor activity.</p>Color and Shape:Odour SolidSJF 1521
CAS:<p>SJF 1521 is an EGFR degrader belonging to the PROTAC class that selectively degrades EGFR while preserving HER2.</p>Formula:C57H61ClFN7O9SPurity:99.20%Color and Shape:SolidMolecular weight:1074.65Tyrosinase-IN-16
CAS:<p>Tyrosinase-IN-16 inhibited tyrosinase.</p>Formula:C8H6BrN3SPurity:99.57%Color and Shape:SolidMolecular weight:256.12SNIPER(ABL)-047
<p>SNIPER(ABL)-047, a compound that links HG-7-85-01 (an ABL inhibitor) to MV-1 (an IAP ligand) via a linker, effectively decreases the BCR-ABL protein levels,</p>Formula:C67H82F3N11O9SPurity:98%Color and Shape:SolidMolecular weight:1274.5SC209
CAS:<p>SC209, a STRO-002 metabolite from patent WO2021247798, synthesizes anti-EGFR ADCs.</p>Formula:C27H44N4O4Color and Shape:SolidMolecular weight:488.66CNX-500
CAS:<p>CNX-500: covalent Btk inhibitor linked to biotin, IC50 0.5 nM, low effect on EGFR and Src kinases.</p>Formula:C48H68N10O9SPurity:98%Color and Shape:SolidMolecular weight:961.18BCR-ABL-IN-3
CAS:<p>BCR-ABL-IN-3 irreversibly inhibits Bcr-Abl with <100 nM IC50, showing significant anti-cancer effects.</p>Formula:C20H17ClF2N4O3SColor and Shape:SolidMolecular weight:466.89SOS1/EGFR-IN-2
<p>SOS1/EGFR-IN-2 (Compound 4) functions as a dual inhibitor of SOS1 and EGFR, exhibiting IC50 values of 8.3 and 14.6 nM, respectively. It demonstrates significant antiproliferative effects on cancer cells harboring various KRAS mutations.</p>Formula:C25H29F3N4O3Color and Shape:SolidMolecular weight:490.52JAK-IN-15
CAS:<p>JAK-IN-15 is a JAK inhibitor. WO2016119700A1 (Compound 15).</p>Formula:C22H23FN4O3SColor and Shape:SolidMolecular weight:442.51VEGFR2/HDAC1-IN-1
<p>VEGFR2/HDAC1-IN-1 (compound 13) is a potent dual inhibitor of VEGFR-2 and HDAC, with IC50 values of 57.83 nM for VEGFR-2 and 9.82 nM for HDAC.</p>Purity:98%Color and Shape:Odour SolidTrastuzumab envedotin
<p>Trastuzumab envedotin (DP303c) is an antibody-drug conjugate (ADC) targeting the human epidermal growth factor receptor 2 (HER2). It consists of the anti-HER2 antibody DP001 linked to the microtubule polymerization inhibitor MonomethylauristatinE (MMAE) through a cleavable linker. This compound is utilized in research involving HER2-positive solid tumors such as breast cancer, colorectal cancer, and gastric cancer.</p>Color and Shape:Odour LiquidTL13-112
CAS:<p>TL13-112 is a selective degrader of ALK-PROTAC and inhibits ALK activity (IC50: 0.14 nM).</p>Formula:C49H60ClN9O10SPurity:98%Color and Shape:SolidMolecular weight:1002.57EGFR-IN-140
<p>EGFR-IN-140 (Compound 31) is an inhibitor of EGFR, effectively targeting both wild-type EGFR and the EGFRL858R/T790M/C797S mutant, with Ki values of 0.95 nM and 2.1 nM, respectively. Additionally, it inhibits EGFRdel19/T790M/C797S in Ba/F3 cells with an IC50 of 56.9 nM and demonstrates antitumor activity in mouse models.</p>Formula:C27H37FN8O2Color and Shape:SolidMolecular weight:524.633LC-MB12
CAS:<p>LC-MB12 is a PROTAC FGFR2 compound that degrades FGFR2 and can be used to study gastric cancer.</p>Formula:C43H44Cl2N10O8Purity:99.16%Color and Shape:SolidMolecular weight:899.78AZ12672857
CAS:<p>AZ12672857 is an inhibitor of EphB4 with IC50 of 1.3 nM.</p>Formula:C26H30N8O2Purity:98.99%Color and Shape:SolidMolecular weight:486.57PROTAC BTK Degrader-1
CAS:<p>Potent, selective oral PROTAC BTK Degrader-1; IC50: 34.51 nM (WT), 64.56 nM (BTK-481S); reduces BTK protein, inhibits tumors.</p>Formula:C43H43N9O4Color and Shape:SolidMolecular weight:749.86K882
<p>K882 (Compound 4e) is an Src inhibitor with a KD of 0.315 μM. It induces apoptosis and inhibits XIAP and Survivin. Additionally, K882 blocks the activation of the PI3K/Akt/mTOR, Jak1/Stat3, and Ras/MAPK signaling pathways. K882 exhibits antitumor activity against non-small cell lung cancer.</p>Formula:C18H16N2O2Color and Shape:SolidMolecular weight:292.33VEGFR/PARP-IN-1
<p>VEGFR/PARP-IN-1 (Compound 14b) is a dual inhibitor of VEGFR and PARP with IC50 values of 191 nM and 60.9 nM, respectively.</p>Formula:C29H27N9OPurity:98%Color and Shape:SolidMolecular weight:517.58Multi-kinase-IN-5
<p>Multi-kinase-IN-5 (compound 15c) is a multi-kinase inhibitory agent that shows significant inhibition against a range of protein kinases including RET, KIT,</p>Formula:C19H15N5O2SColor and Shape:SolidMolecular weight:377.42FAK-IN-24
CAS:<p>FAK-IN-24 (Compound 9f) is a potent FAK inhibitor with an IC50 of 0.815 nM. It induces DNA damage and apoptosis, and exhibits activity against glioblastoma. FAK-IN-24 effectively inhibits proliferation of glioblastoma cell lines U87-MG (IC50= 15 nM) and U251 (IC50= 20 nM), and suppresses tumor growth in U87-MG xenograft models.</p>Formula:C39H45Cl2F3N8O3Color and Shape:SolidMolecular weight:801.728FLT3/VEGFR2-IN-1
<p>FLT3/VEGFR2-IN-1 (Compound 26) is a potent inhibitor of FLT3, VEGFR2, and HDAC, exhibiting IC50 values of 14.5 nM, 3.9 nM, and 30.8 nM against FLT3, VEGFR2, and HDAC1, respectively. It effectively inhibits the phosphorylation of STAT3 and ERK1/2, as well as the proliferation of leukemia cells. FLT3/VEGFR2-IN-1 demonstrates antitumor activity and is applicable in research on acute myeloid leukemia.</p>Formula:C29H35N7O5Color and Shape:SolidMolecular weight:561.63AXL/Angiokinase-IN-1
<p>AXL/Angiokinase-IN-1 (compound 11b) is an inhibitor of AXL/triple angiokinase, with an IC50 of 3.75 nM for AXL expression. This compound suppresses epithelial-mesenchymal transition (EMT) in Bxpc-3 cells and prevents metastasis in lung cancer cells. Additionally, AXL/Angiokinase-IN-1 impairs the functions of vascular and fibroblast cells and induces apoptosis in both cancer and fibroblast cells. It is characterized by low toxicity and favorable metabolic stability.</p>Formula:C31H34ClN5O2Color and Shape:SolidMolecular weight:544.09LC-SF-14
<p>LC-SF-14 is a selective dual inhibitor of SHP2 and FGFR, with IC50 values of 71.6 nM and 8.9 nM, respectively. It blocks FGFR2-FRS2α-SHP2-MAPK signaling and ERK phosphorylation, and also inhibits the proliferation of KATOIII cancer cells (IC50: 9.2 nM). Furthermore, LC-SF-14 exhibits antitumor activity in SNU-16 xenograft mouse models, making it suitable for research on FGFR2-driven gastric cancer.</p>Formula:C44H50Cl3N13O5SColor and Shape:SolidMolecular weight:977.28442SJ988497
CAS:<p>SJ988497: PROTAC JAK2 degrader, inhibits CRLF2r cell growth, degrades GSPT1, combines Ruxolitinib, linker, Pomalidomide; researched for ALL.</p>Formula:C36H36N10O5Color and Shape:SolidMolecular weight:688.74Efruxifermin
CAS:<p>Efruxifermin, a modified FGF21 with IgG1 Fc, has increased stability and affinity. Used in non-alcoholic steatohepatitis research.</p>Color and Shape:LiquidEGFR-IN-86
<p>EGFR-IN-86 (compound 4i), an EGFR inhibitor (IC50: 1.5 nM), demonstrates potent activity against glioblastoma by inducing apoptosis and causing G2/M phase cell</p>Formula:C20H21N7O2SPurity:98%Color and Shape:SolidMolecular weight:423.49Lyso-Monosialoganglioside GM3
CAS:<p>Lyso-Monosialoganglioside GM3 (Lyso-GM3) is an analog of Ganglioside GM3 with antitumor properties. It inhibits the increase in EGFR kinase activity induced by EGF in A431 epithelial cancer cells.</p>Formula:C41H74N2O20Color and Shape:SolidMolecular weight:915.028AKN-028
CAS:<p>AKN-028 is an orally active and potent FLT3 tyrosine kinase inhibitor ( IC 50 = 6 nM). AKN-028 causes dose-dependent inhibition of FLT3 autophosphorylation.</p>Formula:C17H14N6Purity:99.88%Color and Shape:SolidMolecular weight:302.33Ibrutinib dimer
CAS:<p>Ibrutinib dimer is an impurity of Ibrutinib. IIbrutinib dimer is a Dimer of Ibrutinib. Ibrutinib is an irreversible Btk inhibitor (IC50: 0.5 nM).</p>Formula:C50H48N12O4Purity:98%Color and Shape:SolidMolecular weight:880.99JBJ-09-063 TFA
<p>JBJ-09-063 TFA, an EGFR inhibitor selective for EGFR mutations, IC50s: 0.147-0.396 nM, blocks EGFR/Akt/ERK signaling, for EGFR-mutant lung cancer research.</p>Formula:C33H30F4N4O5SColor and Shape:SolidMolecular weight:670.67EGFR-IN-83
<p>EGFR-IN-83 (Compound 9), an EGFR inhibitor with an IC50 of 2.53 nM, exhibits antiproliferative effects on MCF-7 and MDA-MB-231 cell lines, with respective IC50</p>Formula:C22H17F3N4OPurity:98%Color and Shape:SolidMolecular weight:410.39PROTAC BCR-ABL Degrader-1
<p>PROTAC BCR-ABL Degrader-1 (compound PROTAC 1), featuring a 2-oxoethyl linker, promotes Bcr-Abl degradation through the ubiquitin-proteasome pathway and</p>Formula:C43H40N10O6Purity:98%Color and Shape:SolidMolecular weight:792.84HER2-IN-13
CAS:<p>HER2-IN-13 (Compound 33) serves as an effective HER2 inhibitor, exhibiting an IC50 value of 8 nM, and additionally demonstrates inhibition of wt-EGFR with an</p>Formula:C26H23ClF2N8O3Color and Shape:SolidMolecular weight:568.96DSPE-PEG5000-A7R
<p>DSPE-PEG5000-A7R is a PEG compound composed of DSPE and the tumor vascular targeting peptide (A7R). The peptide A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors.</p>Color and Shape:Odour SolidAD57
CAS:<p>AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.</p>Formula:C22H20F3N7OPurity:99.05%Color and Shape:SoildMolecular weight:455.44SA-VA
<p>SA-VA, an intracellular self-assembled PROTAC featuring azide and alkyne groups, selectively degrades VEGFR-2 and EphB4 proteins within U87 cells.</p>Formula:C50H53ClF3N11O7SPurity:98%Color and Shape:SolidMolecular weight:1044.54PROTAC FAK degrader 1
CAS:<p>PROTAC FAK degrader 1 is a selective and potent degrader of focal adhesion kinase (Fak) (IC50 of 6.5 nM).</p>Formula:C47H56F3N9O8S2Purity:98%Color and Shape:SolidMolecular weight:996.13FAK-IN-27
<p>FAK-IN-27 (compound 8A) is a potent and selective inhibitor of FAK, with an IC50 of 4.968 nM. It effectively inhibits the proliferation of H1299 cells, with an IC50 of 0.28 μM, and is applicable for research in non-small cell lung cancer (NSCLC).</p>Formula:C32H28ClN5O6Color and Shape:SolidMolecular weight:613.17281TLT8
<p>TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.</p>Color and Shape:Odour SolidBTK ligand-14
<p>BTKligand-14 is a PROTAC-targeting ligand for BTK, suitable for the synthesis of FDU73.</p>Color and Shape:Odour SolidEGFR-TK-IN-5
<p>EGFR-TK-IN-5 (Compound NCE 2) is a thiazolyl pyrazoline derivative with significant inhibitory activity and stability against EGFR. It is applicable in tumor research.</p>Formula:C26H20ClFN4OSColor and Shape:SolidMolecular weight:490.98DSPE-PEG2000-A7R
<p>DSPE-PEG2000-A7R is a PEG compound consisting of DSPE and a tumor vasculature-targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, a receptor that is overexpressed in various tumors.</p>Color and Shape:Odour SolidMP-RM-1
<p>MP-RM-1 is a selective murine monoclonal antibody inhibitor that targets the human epidermal growth factor receptor 3 (ErbB-3). It blocks ErbB-3 activation induced by neuregulin 1 (NRG-1β), facilitates ErbB-3 internalization and degradation, and inhibits downstream signaling pathways like PI3K-Akt. MP-RM-1 shows potential for research on ErbB-3-overexpressing solid tumors such as breast cancer, melanoma, and prostate cancer.</p>Color and Shape:Odour LiquidEGFR-IN-144
<p>EGFR-IN-144 (Compound 4B) inhibits EGFR (IC50=0.639 µg/mL) and tubulin polymerization (IC50=7.339 µg/mL). It exhibits cytotoxicity in various cancer cells with a GI50 at the nanomolar level. EGFR-IN-144 reduces the expression of mTOR, TNF-α, and IL-6, causes G1/S phase cell cycle arrest, and induces apoptosis.</p>Formula:C20H17Cl2N3O3Color and Shape:SolidMolecular weight:418.273SA-PA
<p>SA-PA, a self-assembled intracellular PROTAC leveraging azide-alkyne click chemistry, selectively degrades VEGFR-2, PDGFR-β, and EphB4 proteins within U87 cells</p>Formula:C40H32ClF3N10O8Purity:98%Color and Shape:SolidMolecular weight:873.19EGFR-IN-43
<p>EGFR-IN-43 (17c) is a potent EGFR inhibitor with ER antagonist action, tamoxifen/endoxifen+gefitinib linkage, and strong anticancer activity.</p>Formula:C50H55ClFN5O5Color and Shape:SolidMolecular weight:860.45ALK-IN-13
CAS:<p>ALK-IN-13 is an ALK inhibitor.</p>Formula:C29H39ClN7O2PColor and Shape:SolidMolecular weight:584.1Axltide
CAS:<p>Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.</p>Formula:C63H107N19O20S2Purity:98%Color and Shape:SolidMolecular weight:1514.77SNIPER(ABL)-019
<p>SNIPER(ABL)-019, a compound that links Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, exhibiting a</p>Formula:C60H77ClN12O9SPurity:98%Color and Shape:SolidMolecular weight:1177.85DSPE-PEG2000-GE11
<p>DSPE-PEG2000-GE11 is a PEG compound composed of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells that overexpress EGFR. DSPE-PEG2000-GE11 is utilized in drug delivery.</p>Color and Shape:Odour Solid(R)-3-Hydroxy Midostaurin
CAS:<p>(R)-3-Hydroxy Midostaurin: potent kinase inhibitor, major midostaurin metabolite via CYP3A4, potential AML treatment.</p>Formula:C35H30N4O5Purity:98%Color and Shape:SolidMolecular weight:586.648BW710
<p>BW710 is an orally active inhibitor specifically targeting fibroblast growth factor receptor 2 (FGFR2). It effectively inhibits the proliferation of BaF3-FGFR2 cells with an IC50 value of 2.8 nM. BW710 completely suppresses FGFR2 enzymatic activity and demonstrates selectivity among 75 tyrosine kinases, including FGFR1, FGFR3, and FGFR4, at a 1 μM concentration. Additionally, BW710 impedes FGFR2 signaling and selectively inhibits the proliferation of cancer cells driven by FGFR2. It exhibits promising pharmacokinetic properties, with an oral bioavailability of 29% in mice.</p>Formula:C28H29FN6O2SColor and Shape:SolidMolecular weight:532.63Duligotuzumab
CAS:<p>Duligotuzumab is a dual-targeting anti-EGFR/HER3 mAb that blocks signaling and induces ADCC for tumors with poor prognosis.</p>Purity:95% - 95%Color and Shape:LiquiddALK-3
<p>dALK-3 is a degrader of anaplastic lymphoma kinase (ALK) that effectively induces the degradation of EML4-ALK with a DC50 of 0.182 μM. It exhibits significant antiproliferative activity against H3122 cells and is applicable for tumor research.</p>Formula:C39H45ClN7O5PColor and Shape:SolidMolecular weight:758.245PROTAC BTK Degrader-2
CAS:<p>PROTAC BTK Degrader-2, a potent degrader of BTK through the PROTAC mechanism, effectively diminishes BTK protein levels [1].</p>Formula:C47H54F2N8O13Color and Shape:SolidMolecular weight:976.97Syk Inhibitor II hydrochloride
CAS:<p>Syk signaling is key in lupus. Syk inhibitors reduce inflammation and sepsis severity in FcgRIIb-/- mice, lowering cytokines and organ damage.</p>Formula:C14H16ClF3N6OPurity:99.05%Color and Shape:SolidMolecular weight:376.77Src Inhibitor 4
<p>Src Inhibitor4 (Compound 18) is a derivative of KX-01 and functions as a Src inhibitor. It effectively disrupts tumor cells, damages microtubules, and induces cell cycle arrest, apoptosis, and immunogenic cell death. After introducing phenol or aniline functional groups, Src Inhibitor4 serves as a payload conjugation site for antibody-drug conjugates, showcasing antitumor activity.</p>Formula:C33H34N4O3Color and Shape:SolidMolecular weight:534.648Si5-N14
CAS:<p>Si5-N14 is a key component of siloxane-linked lipid nanoparticles (SiLNP) with properties that enhance vascular repair and exhibit antitumor activity. In transgenic GFP mouse models, Si5-N14 mediates CRISPR-Cas9 editing. In Lewis lung carcinoma (LLC) tumor mouse models, it leads to the knockdown of vascular endothelial growth factor receptor 2 (VEGFR2), producing antitumor effects. Additionally, in mice with virus-induced lung injury, Si5-N14 facilitates the delivery of fibroblast growth factor-2 (FGF-2) mRNA, promoting vascular repair, oxygenation, and improved lung function. Si5-N14 shows potential for research in tumors, pneumonia, and cardiovascular diseases.</p>Formula:C78H160N6O5Si2Color and Shape:SolidMolecular weight:1318.31DP-C-4
<p>DP-C-4 is a Cereblon-based dual PROTAC for simultaneous degradation of EGFR and PARP[1].</p>Color and Shape:LiquidEGFR/COX-2-IN-1
<p>EGFR/COX-2-IN-1 is an EGFR/COX-2 inhibitor that effectively targets EGFRWT, EGFRT790M, COX-1, and COX-2 with IC50 values of 0.12, 0.076, 20.1, and 1.52 μM, respectively. It inhibits MCF-7, HT-29, and A-549 cells with IC50 values of 1.20, 5.14, and 14.81 μM, respectively. The compound induces apoptosis by upregulating Bax protein and downregulating Bcl-2 protein levels. Additionally, EGFR/COX-2-IN-1 significantly increases the proportion of cells in the G2/M phase in MCF-7 cells, demonstrating a broad-spectrum antitumor effect.</p>Formula:C20H17FN6O2S2Color and Shape:SolidMolecular weight:456.52JAK1/STAT3-IN-1
<p>JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).</p>Formula:C30H33FN4O3SColor and Shape:SolidMolecular weight:548.67PLM-101
<p>PLM-101 is an anticancer compound orally active against acute myeloid leukemia by targeting FLT3 and RET.</p>Formula:C22H22FN5O2Color and Shape:SolidMolecular weight:407.44HDS 029
CAS:<p>HDS 029 has a wide range of applications in life science related research.</p>Formula:C17H11ClFN5OColor and Shape:SolidMolecular weight:355.76Secretin, canine
CAS:<p>Secretin: endocrine hormone, increases bicarbonate-rich pancreatic fluid, regulates canine gastric functions via Src kinase pathway.</p>Formula:C131H222N44O41Purity:98%Color and Shape:SolidMolecular weight:3069.43EGFR/VEGFR2-IN-5
<p>EGFR/VEGFR2-IN-5 (Compound 14) is an orally active dual inhibitor of EGFR and VEGFR2, exhibiting an IC50 value of 1.15 µM for VEGFR2 and 0.28 µM for EGFRT790M. This compound demonstrates significant anticancer activity.</p>Formula:C17H15N7O5SColor and Shape:SolidMolecular weight:429.41EGFR-IN-151
<p>EGFR-IN-151 (Compound 10) inhibits EGFR and its downstream signaling pathways ERK/STAT3. It effectively suppresses the proliferation of various lung cancer cells, with IC50 values of 11.7, 5.19, 7.32, and 1.53 μM for NCI-H1781, HCC827, NCI-H3255, and NCI-H1975, respectively. Additionally, EGFR-IN-151 hinders colony formation and cell migration in H1975, induces G1 phase cell cycle arrest, and triggers apoptosis in H1975 cells.</p>Color and Shape:Odour SolidFGFRs-IN-1
<p>FGFRs-IN-1 (Compound A16) is an orally active inhibitor targeting FGFR1/2/3/4, with IC50 values of 2.3, 7, 11, and 163 nM respectively. It also inhibits VEGFR1/2/3, Abl, and Flt3, with IC50 values of 61, 176, 112, 26, and 353 nM. The compound shows weak inhibition of CYP enzymes. FGFRs-IN-1 reduces the expression of α-SMA and collagen I, and it inhibits epithelial-mesenchymal transition (EMT) in A549 cells stimulated by TGF-β1. Additionally, FGFRs-IN-1 demonstrates anti-inflammatory activity in mouse models of lung fibrosis induced by Bleomycin and liver fibrosis induced by CCl4.</p>Formula:C28H26Cl2N4O3Color and Shape:SolidMolecular weight:537.44MY-1576
<p>MY-1576 is a FAK inhibitor with an IC50 of 8 nM. It activates the Hippo pathway, thereby inhibiting YAP/TAZ regulation. Additionally, MY-1576 effectively suppresses tumor growth in the KYSE30 xenograft mouse model, demonstrates good safety, and efficiently downregulates FAK autophosphorylation and YAP/TAZ levels in vivo.</p>Formula:C25H29ClN8O2Color and Shape:SolidMolecular weight:509Cetuximab (PBS)
<p>Cetuximab (PBS) is a human IgG1 monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), with a dissociation constant (Kd) of 0.201 nM for EGFR as measured by the SPR method. It exhibits potent antitumor activity.</p>Color and Shape:Odour LiquidMulti-kinase-IN-4
<p>Multi-kinase-IN-4 (compound 5d) is a multi-targeted kinase inhibitor active against VEGFR2, EGFR, HER2, and CDK2, with respective IC50 values of 0.33, 0.22, 0.</p>Formula:C21H20ClFN2OSPurity:98%Color and Shape:SolidMolecular weight:402.91Scr-IN-1
<p>Scr-IN-1 (Compound 4e) is a tyrosine kinase inhibitor demonstrating inhibitory activity against HCT-116 and MIA-PaCa-2 cells, with IC50 values of 0.16 μM and 1.16 μM, respectively. It shows selectivity towards HCT-116 cells and MIA-PaCa-2 cells, with a selectivity index (SI) greater than 625 and 86. Scr-IN-1 induces apoptosis in HCT-116 colon cancer cells without altering the proportion of necrotic cells and is a potential novel SRC kinase inhibitor for HCT-116 cells. This compound is suitable for cancer research.</p>Formula:C26H16ClF3N2O3Color and Shape:SolidMolecular weight:496.87MS9427
CAS:<p>MS9427: PROTAC EGFR degrader, 7.1 nM (WT), 4.3 nM (L858R); targets mutant via UPS and autophagy; inhibits NSCLC cell growth; anticancer research.</p>Formula:C48H58ClFN8O12Color and Shape:SolidMolecular weight:993.47SIAIS164018 hydrochloride
<p>SIAIS164018 hydrochloride is a PROTAC-based degrader targeting ALK and EGFR, exhibiting IC50 values of 2.5 nM for ALK and 6.6 nM for ALK G1202R.</p>Formula:C43H49Cl2N10O7PPurity:98%Color and Shape:SolidMolecular weight:919.79SPP-037
<p>SPP-037 is an orally active selective inhibitor of ST6GAL1, with an IC50 of 3.59 μM. It exhibits anti-migration activity against MDA-MB-231 cells by inhibiting integrin α2,6-sialylation and the integrin-FAK-paxillin pathway. In MDA-MB-231 xenograft mouse models, SPP-037 demonstrates antitumor properties. This compound is applicable in breast cancer research.</p>Formula:C36H50ClN3O9SColor and Shape:SolidMolecular weight:735.29563SNIPER(ABL)-044
<p>SNIPER(ABL)-044, a compound that links HG-7-85-01 (ABL inhibitor) to Bestatin (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, achieving a</p>Formula:C51H64F3N9O8SPurity:98%Color and Shape:SolidMolecular weight:1020.17EGFR/BRAFV600E-IN-4
<p>EGFR/BRAFV600E-IN-4 (Compound 10f) is a dual inhibitor of EGFR and BRAFV600E, with IC50 values of 61 nM and 43 nM, respectively. It halts the cell cycle, induces apoptosis in both early and late stages, and inhibits cancer cell growth in vitro, showing broad-spectrum anticancer activity.</p>Formula:C22H16N4OSColor and Shape:SolidMolecular weight:384.45CPD-1224
CAS:<p>CPD-1224, an oral ALK inhibitor derivative, binds cereblon, targets EML4-ALK fusions, and degrades ALK plus L1196M/G1202R mutants.</p>Formula:C43H47ClN8O7SColor and Shape:SolidMolecular weight:855.4Multi-kinase-IN-6
<p>Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that effectively impedes the activity of TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2.</p>Purity:98%Color and Shape:Odour SolidFGFR-IN-19
<p>Arg-IN-1 is a selective covalent inhibitor targeting Arginine (Arg), with IC50 values of 9.7 nM and 30.4 nM for FGFR2 and FGFR3, respectively. This compound is designed to potentially avoid the off-target toxicity of FGFR1/4 and overcome acquired resistance, offering potential in cancer therapies targeting FGFR.</p>Formula:C36H42N12O6Color and Shape:SolidMolecular weight:738.335033-Methylthienyl-carbonyl-JNJ-7706621
CAS:<p>Potent CDK inhibitor 3-Methylthienyl-carbonyl-JNJ-7706621, IC50: CDK1=6.4nM, CDK2=2nM, GSK-3=0.041μM; moderate on CDK4/VEGF-R2/FGF-R2.</p>Formula:C14H14N6O3S2Color and Shape:SolidMolecular weight:378.432-Keto Crizotinib
CAS:<p>2-Keto Crizotinib is an active lactam metabolite of crizotinib.</p>Formula:C21H20Cl2FN5O2Purity:98%Color and Shape:SolidMolecular weight:464.32Amuvatinib hydrochloride
CAS:<p>Amuvatinib HCl (MP470 HCl) is a multi-targeted oral tyrosine kinase inhibitor and hinders RAD51-mediated DNA repair, exhibiting anticancer properties.</p>Formula:C23H22ClN5O3SPurity:98%Color and Shape:SolidMolecular weight:483.97Coumermycin A1
CAS:<p>Coumermycin A1 is a JAK2 signal activator. Coumermycin A1 inhibits DNA Gyrase which thereby inhibits cell division in bacteria.</p>Formula:C55H59N5O20Color and Shape:SolidMolecular weight:1110.092Verucopeptin
CAS:<p>Verucopeptin is a pyranocyclic peptide and HIF-1 inhibitor, an antibiotic effective against B16 melanoma, with anticancer activity.</p>Formula:C43H73N7O13Color and Shape:SolidMolecular weight:896.08TL13-12
CAS:<p>TL13-12 is a selective degrader of ALK-PROTAC and inhibits ALK activity (IC50: 0.69 nM).</p>Formula:C45H53ClN10O10SPurity:98%Color and Shape:SolidMolecular weight:961.49YH32367
<p>YH32367 (ABL105) is a bispecific antibody targeting HER2 and 4-1BB. It induces the secretion of IFN-γ, resulting in the death of tumor cells when co-cultured with hPBMC and HER2-expressing tumor cells. YH32367 demonstrates notable antitumor activity.</p>Color and Shape:Odour LiquidFLT3-IN-28
<p>FLT3-IN-28 (Compound 12y) is an orally active FLT3 inhibitor with antitumor properties. It selectively targets cancer cells with FLT3 internal tandem duplication (ITD) mutations, demonstrating IC50 values of 85, 290, 130, 65, and 220 nM against BaF3-FLT3-ITD, BaF3-TEL-VEGFR2, MV4-11, MOLM-13, and MOLM-14 cell lines, respectively. These lines include acute myeloid leukemia (AML) cells harboring FLT3-ITD mutations such as MV4-11 and MOLM-13/14. The compound also reduces phosphorylation levels of FLT3 and STAT5 in MOLM-13 cells, leading to cell cycle arrest and apoptosis. With an oral bioavailability of 19.2% in SD rats, FLT3-IN-28 extends survival in a dose-dependent manner in MOLM-13 xenografted NSG mouse models. It holds promise for research in FLT3-ITD-related cancer studies.</p>Formula:C23H19FN8O4Color and Shape:SolidMolecular weight:490.447TL13-110
CAS:<p>Negative control for TL 13-112 . Displays no degradation of ALK in cell lines. Highly potent ALK inhibitor (IC50 = 0.34 nM).</p>Formula:C49H62ClN9O9SColor and Shape:SolidMolecular weight:988.59Simotinib hydrochloride
CAS:<p>Simotinib hydrochloride: selective oral EGFR inhibitor, IC50 19.9 nM, potent anticancer agent.</p>Formula:C25H27Cl2FN4O4Color and Shape:SolidMolecular weight:537.41PROTAC EGFR degrader 8
CAS:<p>PROTAC EGFR degrader 8 (T-184) is a PROTAC that selectively degrades the epidermal growth factor receptor (EGFR) with a DC50 of 15.56 nM in HCC827 cells.</p>Formula:C40H46ClN11O5Purity:98%Color and Shape:SolidMolecular weight:796.32DSPE-PEG1000-A7R
<p>DSPE-PEG1000-A7R is a PEG compound consisting of DSPE and the tumor vasculature-targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors.</p>Color and Shape:Odour SolidAnticancer agent 271
<p>Anticanceragent 271 (compound 5C) exhibits antiproliferative activity against lung cancer (A549), colon cancer (Caco-2) cell lines, and human lung fibroblasts (WI38), with an IC50 value of 9.18 μM for A549 cells. This compound can downregulate PI3K and mTOR gene expression and is applicable in cancer research.</p>Color and Shape:Odour SolidWu-5
CAS:<p>Wu-5 is a potent USP10 inhibitor that inhibits FLT3 and AMPK pathways, promoting the breakdown of FLT3-ITD and inducing apoptosis.</p>Formula:C15H13NO7SPurity:99.29%Color and Shape:SoildMolecular weight:351.33MTX-241F
<p>MTX-241F, a selective small molecule inhibitor, targets members of the EGFR and PI3 kinase families.</p>Formula:C20H14ClFN6Purity:98%Color and Shape:SolidMolecular weight:392.82BTK inhibitor 19
CAS:<p>BTK inhibitor 19 is a highly selective, covalent BTK inhibitor ( IC 50 = 2.7 nM).</p>Formula:C25H24F3N7O3Color and Shape:SolidMolecular weight:527.508EGFR-IN-78
<p>EGFR-IN-78 (compound A5), a 2-aminopyrimidine derivative, serves as a reversible EGFR C797S-TK inhibitor and an apoptosis inducer.</p>Formula:C23H32BrN7O2SPurity:98%Color and Shape:SolidMolecular weight:550.51PST3.1a
CAS:<p>PST3.1a is a selective inhibitor of Mannoside acetyl glucosaminyltransferase 5 (MGAT5), used for studying glioblastoma multiforme (GBM). PST3.1a inhibits TGF-βR and FAK signalling associated with doublecortin (DCX), increases OLIG2 expression, and suppresses the invasion and proliferation of GBM initiator cells (GICs).</p>Formula:C32H33O6PColor and Shape:SolidMolecular weight:544.57GBD-9
CAS:<p>GBD-9, a dual-mechanism degrader, effectively promotes the degradation of BTK and GSPT1 through recruitment of E3 ligase cereblon (CRBN).</p>Formula:C44H47N9O6Purity:98%Color and Shape:SolidMolecular weight:797.9ML 2-23
<p>ML 2-23 is a potent BCR-ABL degrader operating as a PROTAC, exhibiting selective proteasome-dependent degradation of BCR-ABL within leukemia cells [1].</p>Formula:C47H53BrCl2N10O7SPurity:98%Color and Shape:SolidMolecular weight:1052.86hCA/VEGFR-2-IN-3
<p>hCA/VEGFR-2-IN-3 (compound 8j) is an indolinonylbenzenesulfonamide with potential as a dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2.</p>Formula:C24H28N6O6SPurity:98%Color and Shape:SolidMolecular weight:528.58Syk Kinase Peptide Substrate, Biotin labeled
<p>The compound, Biotin-labeled Syk Kinase Peptide Substrate, is a peptide substrate of Syk kinase that is labeled with biotin.</p>Formula:C76H108N18O24S1Color and Shape:SolidMolecular weight:1689.9PROTAC EGFR degrader 3
CAS:<p>Potent PROTAC EGFR degrader 3; excellent against H1975/HCC827 cells; lysosome-involved mutant degradation.</p>Formula:C60H77N13O5SColor and Shape:SolidMolecular weight:1092.4Varlitinib Tosylate
CAS:<p>Varlitinib Tosylate is a selective and potent inhibitor of ErbB1(EGFR) and ErbB2(HER2).</p>Formula:C36H35ClN6O8S3Purity:98%Color and Shape:SolidMolecular weight:811.34Lyn peptide inhibitor
CAS:<p>Inhibits Lyn kinase, blocks IL-5 receptor, prevents eosinophil differentiation and reduces asthma-related inflammation in mice.</p>Formula:C115H184N30O24Purity:98%Color and Shape:SolidMolecular weight:2370.91PROTAC FGFR1 degrader-1
<p>PROTAC FGFR1 degrader-1 (compound S2H) is a targeted degrader of FGFR1, demonstrating an IC50 of 26.81 nM and a DC50 of 39.78 nM in KG1a cells. This compound is composed of a CRBN-type E3 ligase ligand (blue part) Pomalidomide, a target protein ligand (red part) FGFR1ligand-1, and a PROTAC linker (black part) 9-Bromononanoic acid, together forming the conjugate E3LigaseLigand-linker Conjugate 164.</p>Formula:C46H54N8O8Color and Shape:SolidMolecular weight:846.97Tephrosin
CAS:<p>Tephrosin induces degradation of of EGFR and ErbB2 by inducing internalization of the receptors, has potent antitumor activities.</p>Formula:C23H22O7Purity:98%Color and Shape:SolidMolecular weight:410.42PROTAC BCR-ABL1 ligand 1
CAS:<p>GMB-475 is a PROTAC ligand targeting BCR-ABL1 for degradation via E3 ligase recruitment.</p>Formula:C17H12F3N3O2Color and Shape:SoildMolecular weight:347.29COVA208
<p>COVA208 is a bispecific FynomAb targeting HER2, consisting of a fusion protein of an antibody and a FynSH3-derived binding protein. It induces the degradation of HER2, reducing the levels of HER2, HER3, and EGFR, effectively blocking downstream signaling pathways such as HER3-PI3K-AKT and MAPK, and inducing apoptosis in tumor cells. COVA208 shows promise for research in cancers like HER2-positive breast, gastric, and colorectal cancers.</p>Color and Shape:Odour LiquidhCA/VEGFR-2-IN-4
<p>hCA/VEGFR-2-IN-4 (compound 15b), an indolinylbenzenesulfonamide, serves as a potential dual inhibitor targeting cancer-related human carbonic anhydrases hCA IX/</p>Formula:C22H23FN6O5SPurity:98%Color and Shape:SolidMolecular weight:502.52PACAP-38 (31-38), human, mouse, rat TFA
<p>PACAP-38 (31-38), human, mouse, rat (TFA) demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal.</p>Formula:C49H84F3N17O13Purity:98%Color and Shape:SolidMolecular weight:1176.29VnP-16
<p>VnP-16 enhances bone formation by stimulating the differentiation and activity of osteoblasts via direct β1 integrin engagement, which subsequently activates</p>Formula:C82H112N20O17Purity:98%Color and Shape:SolidMolecular weight:1649.89EGFR/CDK2-IN-3
<p>EGFR/CDK2-IN-3 (compound 4b) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 71.7 nM and 113.7 nM, respectively.</p>Formula:C30H20N6OSPurity:98%Color and Shape:SolidMolecular weight:512.58AMX-818
<p>AMX-818 is a conditionally activated, masked T cell engager (TCE) that targets HER2. It demonstrates potent T cell cytotoxicity against HER2-positive tumor cell lines and can induce tumor regression in vivo. AMX-818 holds promise for research into HER2-positive solid tumors.</p>Color and Shape:Odour LiquidEGFR/BRAFV600E-IN-3
<p>EGFR/BRAFV600E-IN-3 is an inhibitor targeting EGFR, BRAFV600E, and EGFRT790M with IC50 values of 57 nM, 68 nM, and 9.70 nM, respectively.</p>Formula:C25H18N4O3Purity:98%Color and Shape:SolidMolecular weight:422.44Antifibrotic agent 1
<p>Antifibrotic agent 1 is an orally active medication designed to treat idiopathic pulmonary fibrosis (IPF). It effectively mitigates IPF-related processes, including TGF-β-induced epithelial-mesenchymal transition (EMT) and fibroblast-to-myofibroblast transition (FMT), as well as profibrotic M2 polarization. Antifibrotic agent 1 selectively inhibits CSF-1R, PDGFR-α, and Src family kinases (SFKs), while sparing VEGFR, FGFR, and Abl to minimize off-target toxicity. In a bleomycin (BLM)-induced pulmonary fibrosis mouse model, it demonstrates strong antifibrotic activity.</p>Formula:C27H23ClN6O2Color and Shape:SolidMolecular weight:498.1571MS9427 TFA
<p>MS9427 TFA: PROTAC EGFR degrader, Kd 7.1 nM (WT), 4.3 nM (L858R), targets mutant EGFR, inhibits NSCLC cell growth, for cancer research.</p>Formula:C50H59ClF4N8O14Color and Shape:SolidMolecular weight:1107.5IBI-334
<p>IBI-334 is a bispecific antibody targeting both B7-H3 and EGFR. It features an EGFR arm responsible for signal blocking, connected to a modified B7-H3 arm that ensures optimal affinity and binding. The antibody is afucosylated to enhance its antibody-dependent cellular cytotoxicity (ADCC) effects. IBI-334 is widely applicable in EGFR-driven solid tumors.</p>Color and Shape:Odour LiquidSJ1008030 formic
<p>SJ1008030 (compound 8) formic is a selective JAK2 degrader within the PROTAC class, demonstrating efficacy in inhibiting MHH-CALL-4 leukemia cell growth with an</p>Formula:C43H45N13O9SPurity:98%Color and Shape:SolidMolecular weight:919.96IMC-D11
<p>IMC-D11 (LY-3076226 antibody) is an IgG1 monoclonal antibody targeting FGFR3. It serves as the antibody component of LY3076226. For its isotype control, refer to Human IgG1 kappa, Isotype Control.</p>Color and Shape:Odour LiquidE7090
CAS:<p>E-7090 is a fibroblast growth factor receptor inhibitor. E-7090 is a selective inhibitor of the tyrosine kinase activities of FGFR1, -2, and -3.</p>Formula:C32H37N5O6Color and Shape:SolidMolecular weight:587.67Abl Cytosolic Substrate
CAS:<p>Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ).</p>Formula:C64H101N15O16Purity:98%Color and Shape:SolidMolecular weight:1336.58ABP-102
<p>ABP-102 (CT P72) is a bispecific t-cell adduct (BiTE) that acts as a CD3 modulator and selective HER2 modulator for targeting HER2 overexpressing tumors.</p>Color and Shape:Odour LiquidJAK/HDAC-IN-2
<p>JAK/HDAC-IN-2, a potent 2-amino-4-phenylaminopyrimidine dual-target inhibitor, effectively suppresses JAK1/2 and HDAC3/6 at nanomolar concentrations.</p>Formula:C28H38N6O5SPurity:98%Color and Shape:SolidMolecular weight:570.7
